Coronavirus Disease 2019(COVID-19) COVID-19
Conditions
Interventions
Patients with COVID-19 will be randomly assigned to any of the following groups:
-Standard treatment group
-Standard treatment +nafamostat mesilate 0.2mg/kg/hr group, 6 days(110-120hrs)
-Standard tre
Sponsors
Okugawa Shu
Moriya Kyoji
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients who have given written consent to participate in the study 2)SARS-CoV-2 PCR Positive 3) Patients in need of inpatient treatment 4)Patents with no obvious pneumonia on chest images 5)Patients who are hospitalized and can start study drug administration within 5days after the onset of COVID-19 symptoms
Exclusion criteria
Exclusion criteria: 1)Patients with recurrence or reinfection of COVID-19 2) Patients who are asymptomatic or whose onset date of various symptoms due to COVID-19 cannot be specified 3) Patients suspected of having infection with microorganisms other than SARS-CoV-2 requiring treatment 4) Patients with hyperkalemia or hyponatremia 5) Patients undergoing or planning treatment for malignant tumors 6) Patients with severe liver dysfunction or renal dysfunction requiring dialysis 7) Patients with impaired consciousness such as disorientation 8)Patients who are pregnant or who may be pregnant 9) Patients with weakened immune system 10)Patients with a history of hypersensitivity to Nafamostat Mesilate 11)Patients who are considered inappropriate for inclusion in the study by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUC of SARS-CoV-2 virus reduction in the nasopharynx from before the start of treatment to the 6th day of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Change of clinical symptoms (vital sign, SpO2) 2)Amount of change in patient condition on a 10-point scale 3) Logarithmic viral load | — |
Contacts
Public ContactShu Okugawa
The University of Tokyo Hospital
Outcome results
None listed